Literature DB >> 18024371

The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.

Steven Le Gouill1, Pascaline Talmant, Cyrille Touzeau, Anne Moreau, Richard Garand, Nadine Juge-Morineau, Fanny Gaillard, Thomas Gastinne, Noël Milpied, Philippe Moreau, Jean Luc Harousseau, Hervé Avet-Loiseau.   

Abstract

BACKGROUND AND OBJECTIVES: Diffuse large B-cell lymphomas (DLBCL) are common lymphomas that have been classified into three subgroups on the basis of their patterns of gene expression. The aim of this study was to characterize the clinical, biological, immunophenotypic and cytogenetic features of DLBCL with concurrent t(14;18) and 8q24/c-MYC rearrangement. DESIGN AND METHODS: Sixteen cases of DLBCL with the dual translocation were identified between 1998 and January 2006. The clinical features of these cases were examined and morphological, immunohistochemical, flow cytometric and cytogenetic analyses were performed.
RESULTS: All patients had aggressive features: B symptoms (81%), ECOG performance status >2 (81%), elevated lactate dehydrogenase (100%), stage IV disease (100%) with at least one extra-nodal localization (bone marrow, blood and central nervous system involvement in 93%, 50% and 50%, respectively) and age-adjusted IPI score of 3 in 81%. Despite intensive chemotherapy regimens (including allogeneic transplants), all patients died of disease progression. Progression-free and overall survival was 4 and 5 months, respectively. Immunophenotyping analysis (CD20, CD10, Bcl-6, Mum-1, Bcl-2 CD138, MIB1, CD19, CD5, CD38 and sIg) was performed and showed DLBCL with a germinal center (GC) profile. Ki-67 staining ranged from 70 to 90%. All cases assessed by cytogenetics analysis [conventional cytogenetic and/or fluorescence in situ hybridization (FISH)] had a complex karyotype. In one case, we identified a 8q24/c-MYC translocation variant never reported in DLBCL before: t(8;9)(q24;p13) and t(14;18)(q32;q21). The BCL-6 rearrangement was investigated by FISH and found to rearranged in four cases. INTERPRETATION AND
CONCLUSIONS: In conclusion, DLBCL with concurrent t(14;18) and 8q24/c-MYC rearrangement is a subgroup of GC-DLBCLwith poor outcome. It is worth searching for the coexistence of dual translocations in Bcl-2-positive DLBCL with unusual aggressive presentation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18024371     DOI: 10.3324/haematol.11305

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  52 in total

1.  MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.

Authors:  Wendy Cuccuini; Josette Briere; Nicolas Mounier; Hans-Ullrich Voelker; Andreas Rosenwald; Christer Sundstrom; Sergio Cogliatti; Edouard Hirchaud; Loic Ysebaert; Dominique Bron; Jean Soulier; Philippe Gaulard; Remi Houlgatte; Christian Gisselbrecht; Catherine Thieblemont
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

Review 2.  Biology of double-hit B-cell lymphomas.

Authors:  R Coleman Lindsley; Ann S LaCasce
Journal:  Curr Opin Hematol       Date:  2012-07       Impact factor: 3.284

3.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

4.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

Authors:  Lisa M Rimsza; Michael L Leblanc; Joseph M Unger; Thomas P Miller; Thomas M Grogan; Daniel O Persky; Ralph R Martel; Constantine M Sabalos; Bruce Seligmann; Rita M Braziel; Elias Campo; Andreas Rosenwald; Joseph M Connors; Laurie H Sehn; Nathalie Johnson; Randy D Gascoyne
Journal:  Blood       Date:  2008-06-10       Impact factor: 22.113

5.  Establishment of CD5 and CD10 double-positive mature B-cell line, WILL1, showing complex 8q24 translocation involving 14q32 and 6q27.

Authors:  Shima Uneda; Minako Gotoh; Takashi Sonoki; Kazuhiro Nishida; Yasushi Nakamura; Miwa Kurimoto; Nobuyoshi Hanaoka; Hiroshi Matsuoka; Masafumi Taniwaki; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2008-10-30       Impact factor: 2.490

6.  Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Authors:  Sietse M Aukema; Markus Kreuz; Christian W Kohler; Maciej Rosolowski; Dirk Hasenclever; Michael Hummel; Ralf Küppers; Dido Lenze; German Ott; Christiane Pott; Julia Richter; Andreas Rosenwald; Monika Szczepanowski; Carsten Schwaenen; Harald Stein; Heiko Trautmann; Swen Wessendorf; Lorenz Trümper; Markus Loeffler; Rainer Spang; Philip M Kluin; Wolfram Klapper; Reiner Siebert
Journal:  Haematologica       Date:  2013-10-31       Impact factor: 9.941

Review 7.  Transformation of follicular lymphoma.

Authors:  Izidore S Lossos; Randy D Gascoyne
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-06       Impact factor: 3.020

Review 8.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

Review 9.  [Grey zone lymphomas: limitations of the classification of aggressive B-cell lymphomas].

Authors:  M M Ott; H Horn; A Rosenwald; G Ott
Journal:  Pathologe       Date:  2013-05       Impact factor: 1.011

Review 10.  [Grayzone lymphoma. Clinical relevance].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.